Filtered By:
Condition: Hypertension
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 256 results found since Jan 2013.

Effect of Age on Treatment, Trends and Outcome of Patients Hospitalized With Atrial Fibrillation: Insights From a 20-Years Registry in a Middle-eastern Country (1991-2010).
Conclusion: Anticoagulation remains underutilized in elderly patients with AF despite proven efficacy and increasing trends of cardiovascular comorbidities. The current study underscores the urgent need for prospective studies to investigate warfarin contraindications, relative warfarin efficacy and bleeding risks in our region to help guide healthcare providers in warfarin prescribing in this frail patient population and consequently reduce the risk of AF-related disabling strokes and mortality. PMID: 23211770 [PubMed - as supplied by publisher]
Source: Aging Clinical and Experimental Research - November 26, 2012 Category: Geriatrics Authors: Salam AM, Albinali HA, Al-Sulaiti EM, Al-Mulla AW, Singh R, Al Suwaidi J Tags: Aging Clin Exp Res Source Type: research

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries
Source: Annals of Pharmacotherapy Area: Evidence > Medicines Management > References Background: Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low.  In 2008, the US Medicare Part D programme was expanded to pay for medications for Medicare enrollees. Objective: To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF. Methods: This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in ...
Source: NeLM - Cardiovascular Medicine - January 24, 2013 Category: Cardiology Source Type: news

National Heart Foundation of Australia consensus statement on catheter ablation as a therapy for atrial fibrillation.
Abstract Atrial fibrillation (AF) is estimated to affect 1%-2% of the population. It is increasing in prevalence and is associated with excess mortality, considerable morbidity and hospitalisations. AF is responsible for a significant and growing societal financial burden. Catheter ablation is an increasingly used therapeutic strategy for the management of AF; however, some confusion exists among those caring for patients with this condition about the role and optimal use of ablative treatments for AF. Our aim in this consensus statement is to provide recommendations on the use of primary catheter ablation for AF ...
Source: Med J Aust - January 21, 2013 Category: Journals (General) Authors: Kalman JM, Sanders P, Brieger DB, Aggarwal A, Zwar NA, Tatoulis J, Tay AE, Wilson A, Branagan MG Tags: Med J Aust Source Type: research

Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study.
Conclusion: These results demonstrate the necessity for improved quality of physician care of patients with AF, especially with regards to antithrombotic therapy. PMID: 23666295 [PubMed - in process]
Source: Turk Kardiyoloji Dernegi arsivi - March 1, 2013 Category: Cardiology Authors: Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, Kahya Eren N, Cağlıyan CE, Köroğlu B, Vatan B, Acar G, Yüksel M, Bilik MZ, Gedik S, Simşek Z, Akıl MA, Yılmaz R, Oylumlu M, Arıbaş A, Yıldız A, Aydın M, Yeter E, Kanadaşı M, Ergene O, Ozha Tags: Turk Kardiyol Dern Ars Source Type: research

Medical management of critical limb ischaemia: where do we stand today?
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - June 26, 2013 Category: Internal Medicine Authors: Matthew A. Lambert, Jill J. F. Belch Tags: Review Source Type: research

Risk of Subarachnoid Hemorrhage and Early Case Fatality Associated With Outpatient Antithrombotic Drug Use Clinical Sciences
Conclusions— Outpatient antithrombotic drug use was associated with an increased risk of SAH, but no association was observed with early case fatality.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Garbe, E., Kreisel, S. H., Behr, S. Tags: Heparin, Coumarins, Platelet function inhibitors, Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Clinical Sciences Source Type: research

Oral Anticoagulation Therapy for Elderly Patients With Atrial Fibrillation: Utility of Bleeding Risk Covariates to Better Understand and Moderate Risks
Elderly individuals are prone to nonvalvular atrial fibrillation (AF) with associated risks of arterial thromboembolic disease. Despite definitive guidelines, oral anticoagulant therapy (OAC) is notoriously underutilized in patients with AF. Physicians cite excessive bleeding risk as one reason they omit OAC for their older patients with AF. Improved understanding of the pathophysiology of age-related bleeding may improve risk–benefit assessments for warfarin and newer antithrombotic agents. We reviewed the literature to identify age-related pathophysiological elements that can exacerbate the likelihood of bleeding. ...
Source: Clinical and Applied Thrombosis/Hemostasis - December 12, 2013 Category: Hematology Authors: Forman, D. E., Goyette, R. E. Tags: Original Articles Source Type: research

Intracranial Hemorrhages Related with Warfarin Use and Comparison of Warfarin and Acetylsalicylic Acid
Conclusions: Use of warfarin, low GCS score, opening to ventricle, older age, accompanying diabetes, and/or hypertension were worse prognostic factors. It is possible that patients with these unfavorable prognostic factors cannot survive.
Source: Journal of Stroke and Cerebrovascular Diseases - April 5, 2013 Category: Neurology Authors: Yaprak Seçil, Yeliz Çiftçi, Figen Tokuçoğlu, Yeşim Beckmann Tags: Original Articles Source Type: research

Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation Results From a Multicenter Prospective Registry
ConclusionsUninterrupted rivaroxaban therapy appears to be as safe and efficacious in preventing bleeding and thromboembolic events in patients undergoing AF ablation as uninterrupted warfarin therapy.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 10, 2014 Category: Cardiology Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation
Atrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF. Warfarin is successfully used to reduce thromboembolic events. More recently, direct thrombin (dabigatran) and factor Xa (apixaban, edoxaban, rivaroxaban) inhibitors have been compared to warfarin in large randomized trials. All new substances have been shown to be non-inferior to warfarin concerning thromboembolic events...
Source: Seminars in Hematology - April 9, 2014 Category: Hematology Authors: Georg Noll, Sarah Noll, David Hürlimann Source Type: research

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
ConclusionsIn this large observational study, the MB rate was generally consistent with the registration trial results, and fatal bleeds were rare.
Source: Clinical Cardiology - December 1, 2014 Category: Cardiology Authors: Sally Tamayo, W. Frank Peacock, Manesh Patel, Nicholas Sicignano, Kathleen P. Hopf, Larry E. Fields, Troy Sarich, Shujian Wu, Daniel Yannicelli, Zhong Yuan Tags: Quality and Outcomes Source Type: research

Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial.
CONCLUSION: TTR values among PAC-managed patients with nonvalvular atrial fibrillation were comparable to those reported in the RE-LY trial. PMID: 25788509 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - March 20, 2015 Category: Drugs & Pharmacology Authors: Biszewski M, Nitzki-George D, Zhou Y Tags: Am J Health Syst Pharm Source Type: research

Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin
We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Source: The American Journal of Cardiology - June 24, 2015 Category: Cardiology Authors: Siqin Ye, Bin Cheng, Gregory Y.H. Lip, Richard Buchsbaum, Ralph L. Sacco, Bruce Levin, Marco R. Di Tullio, Min Qian, Douglas L. Mann, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, J.P. Mohr, Susan Graham, Arthur J. Labovitz, Conrado J. Tags: Heart Failure Source Type: research

Use of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation　- Subanalysis of the J-RHYTHM Registry.
CONCLUSIONS: Warfarin could have beneficial effects even in very old NVAF patients if INR is kept between 1.6 and 2.59. PMID: 26329097 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 1, 2015 Category: Cardiology Authors: Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, J-RHYTHM Registry Investigators Tags: Circ J Source Type: research

Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
Conclusions: In this small prospective observational study, patients with NOAC-associated ICH had smaller ICH volumes and better clinical outcomes compared with warfarin-associated ICH.
Source: Neurology - January 25, 2016 Category: Neurology Authors: Wilson, D., Charidimou, A., Shakeshaft, C., Ambler, G., White, M., Cohen, H., Yousry, T., Al-Shahi Salman, R., Lip, G. Y. H., Brown, M. M., Jager, H. R., Werring, D. J., On behalf of the CROMIS-2 collaborators Tags: Prognosis, Clinical trials Observational study (Cohort, Case control), Intracerebral hemorrhage ARTICLE Source Type: research